Author: Robin Hamilton (United Kingdom)
Co-authors: Konstantinos Balaskas, Sesan Oyetunde, Kuldip Grewal, Fiona Glen, Luke Saunders, Louise Downey
Purpose
Age-related macular degeneration (AMD) is the leading cause of blindness in the United Kingdom (UK), with the number of new cases and associated costs to the UK economy continuing to rise alongside an increase in life expectancy and an ageing population. In the UK, the standard therapy for treatment of neovascular AMD (nAMD) is intravitreal injection of anti–vascular endothelial growth factor (anti-VEGF) therapy. Prompt intervention with anti-VEGF treatment and continued maintenance of therapy following early diagnosis of nAMD is paramount to providing disease control and preserving the vision of patients, with treatment delays likely to lead to irreversible visual loss and subsequent higher social support costs. There has, however, been limited research investigating anti-VEGF treatment patterns and associated clinical outcomes within real-world clinical practice in the UK. The objective of this retrospective non-interventional study was to describe the current management landscape for patients with nAMD treated with anti-VEGF therapy in the UK and associated clinical outcomes during the first 24 months after initiating treatment.
Setting/Venue
The RATE study for nAMD involved the collection of pseudonymised patient and service-level data about current treatment practices and outcomes for patients newly initiated on licensed anti-VEGF therapy at eighteen hospitals within the UK National Health Service. Participating centres were from a diverse setting of teaching and district general hospitals spread geographically across England and Wales. Data were collected using a mixed-methodology approach that involved the retrospective review of patient medical records, additional independent interpretation of medical imaging results and a service mapping survey with healthcare professionals: early results from the medical record review are presented here.
Methods
Patients were sequentially included if they had been initiated on a licensed anti-VEGF therapy (aflibercept or ranibizumab) for nAMD and received ≥1 intravitreal injection between 01/01/2017 and 31/12/2017. (The date of the first injection is the ‘index date’; the eye that received first injection is the ‘index eye’). Patients were required to be aged ≥50 years at index, have a first diagnosis of nAMD on or within 60 days prior to the index date, and be anti-VEGF treatment naive in both eyes. Data were analysed using descriptive statistics (analyses included data on the index eye only). Key treatment and clinical outcomes during the 12 months post-index are presented here. For the purpose of this analysis, disease control was defined as the absence of retinal fluid (no intra-retinal [IRF] and no sub-retinal fluid [SRF]), as documented in medical records by the treating physician in relation to the most recent optical coherence tomography (OCT) result at Month 12 (±2 months). OCT scans were also independently assessed by a central reading centre and these data will form the basis of further analyses. Change in visual acuity (VA) from baseline (the closest pre-index measurement) was assessed in Early Treatment Diabetic Retinopathy Study (ETDRS) letters.
Results
Of the 331 patients included in this analysis, the median (interquartile range [IQR]) age at index was 79 (74–84) years and 200 (60%) patients were female. The median (IQR) duration from nAMD diagnosis until first anti-VEGF injection was 2 (0–11.5) days. All patients received a NICE-approved anti-VEGF therapy for nAMD: 194 (59%) patients received aflibercept and 137 (41%) received ranibizumab. 313 (95%) patients received at least three anti-VEGF injections within 90 days after the index date, with patients receiving a mean (standard deviation [SD]) of 7.3 (2.0) injections during the 12 months post-index. Of 256 patients with available information on IRF and SRF status and at least 12 months follow-up, 117 (46%) were documented to have achieved disease control in the index eye at Month 12. The median (IQR) VA at baseline (n=304) was 55.0 (45.0 - 65.0) ETDRS letters. There was a median (IQR) increase in VA from baseline of 6.5 (0.0–15.0) letters at Month 3 (n=300), 7.0 (0.0–16.0) letters at Month 6 (n=286), 9.0 (0.2–16.0) letters at Month 9 (n=270) and 7.0 (0.0–18.0) letters at Month 12 (n=253 [all p<0.001]).
Conlusions
Early results from the RATE study indicated that at month 12, disease control was achieved in approximately half of patients initiated on a licensed anti-VEGF therapy, with VA improving by a median of 7 letters. Within UK clinical practice, there was prompt access to anti-VEGF treatment (within 2 days on average of diagnosis) and 95% of patients received ≥3 anti-VEGF injections within 90 days, in alignment with recommendations that a loading phase of three injections at monthly intervals is completed for patients newly initiated on treatment. Patients received a mean of 7.3 injections in total within the first year, suggesting that centres are opting to extend the intervals between injections after completion of the loading phase (the service mapping analysis completed as part of this study will further clarify treatment protocols used within these centres). It will also be important to understand the extent to which service capacity issues, treatment protocols and VA outcomes influence treatment interval decisions. Further planned analyses will consider wider aspects of the management and visual outcomes of patients with nAMD during the first 24 months of treatment, including anti-VEGF regimens and treatment patterns and the wider structure of UK retinal services.
Financial Disclosure
Robin Hamilton: Consultant for Allergan, Bayer Healthcare, Novartis Pharmaceuticals, and Roche; Receives grants from Bayer Healthcare, Novartis Pharmaceuticals and Roche; Receives lecture fees from Allergan, Roche, Bayer Healthcare, and Novartis Pharmaceuticals. Sesan Oyetunde: Employee of Novartis Pharmaceuticals UK. Kuldip Grewal: Employee of Novartis Pharmaceuticals UK. Fiona Glen: Employee of Open Health, who have received funding from Novartis Pharmaceuticals UK. Luke Saunders: Employee of Open Health, who have received funding from Novartis Pharmaceuticals UK. Konstantinos Balaskas: Consultant for Novartis and Roche; Research grants from Bayer Healthcare, Novartis Pharmaceuticals, Roche, Apellis; Speaker fees from Roche, Bayer, Novartis, Alimera, Heidelberg engineering. Louise Downey: Consultant for Alimera, Allergan, Bayer Healthcare, Novartis Pharmaceuticals, and Roche; Receives grants from Allergan, Bayer Healthcare and Novartis Pharmaceuticals; Receives lecture fees from Alimera, Allergan, Bausch and Lomb, Bayer Healthcare, Novartis Pharmaceuticals and Roche.
Comments
-